Antibody therapy for Lassa fever

Robert Cross, Kathryn M. Hastie, Chad Mire, James E. Robinson, Thomas Geisbert, Luis M. Branco, E. Ollmann Saphire, Robert F. Garry

Research output: Contribution to journalReview article

Abstract

Serum from convalescent Lassa fever patients was previously shown to be ineffective as a source of protective antibodies in some early studies. Subsequently, monoclonal antibodies (MAbs) to the Lassa virus (LASV) glycoprotein produced by memory B cells of West African patients who survived Lassa fever were identified. Development of MAbs as potential Lassa immunotherapeutics was facilitated by structural studies and mutational analyses that identified protective epitopes on the prefusion form of the LASV glycoprotein. Human mAbs were screened for reactivity to different neutralizing epitopes, potency, and broad reactivity against multiple lineages of LASV. MAbs were downselected in a guinea pig model of Lassa fever. A cocktail of three human MAbs designated Arevirumab-3 rescued 100% of Cynomolgus macaques at advanced stages of disease more than a week post-infection. Antibody therapeutics may be further developed in clinical trials in endemic areas potentially offering a key treatment option for Lassa fever.

Original languageEnglish (US)
Pages (from-to)97-104
Number of pages8
JournalCurrent Opinion in Virology
Volume37
DOIs
StatePublished - Aug 1 2019

Fingerprint

Lassa Fever
Lassa virus
Monoclonal Antibodies
Antibodies
Epitopes
Glycoproteins
Macaca
Therapeutics
Guinea Pigs
B-Lymphocytes
Clinical Trials
Infection
Serum

ASJC Scopus subject areas

  • Virology

Cite this

Antibody therapy for Lassa fever. / Cross, Robert; Hastie, Kathryn M.; Mire, Chad; Robinson, James E.; Geisbert, Thomas; Branco, Luis M.; Ollmann Saphire, E.; Garry, Robert F.

In: Current Opinion in Virology, Vol. 37, 01.08.2019, p. 97-104.

Research output: Contribution to journalReview article

Cross, R, Hastie, KM, Mire, C, Robinson, JE, Geisbert, T, Branco, LM, Ollmann Saphire, E & Garry, RF 2019, 'Antibody therapy for Lassa fever', Current Opinion in Virology, vol. 37, pp. 97-104. https://doi.org/10.1016/j.coviro.2019.07.003
Cross, Robert ; Hastie, Kathryn M. ; Mire, Chad ; Robinson, James E. ; Geisbert, Thomas ; Branco, Luis M. ; Ollmann Saphire, E. ; Garry, Robert F. / Antibody therapy for Lassa fever. In: Current Opinion in Virology. 2019 ; Vol. 37. pp. 97-104.
@article{f5cb9ba503544348b723988d3a069749,
title = "Antibody therapy for Lassa fever",
abstract = "Serum from convalescent Lassa fever patients was previously shown to be ineffective as a source of protective antibodies in some early studies. Subsequently, monoclonal antibodies (MAbs) to the Lassa virus (LASV) glycoprotein produced by memory B cells of West African patients who survived Lassa fever were identified. Development of MAbs as potential Lassa immunotherapeutics was facilitated by structural studies and mutational analyses that identified protective epitopes on the prefusion form of the LASV glycoprotein. Human mAbs were screened for reactivity to different neutralizing epitopes, potency, and broad reactivity against multiple lineages of LASV. MAbs were downselected in a guinea pig model of Lassa fever. A cocktail of three human MAbs designated Arevirumab-3 rescued 100{\%} of Cynomolgus macaques at advanced stages of disease more than a week post-infection. Antibody therapeutics may be further developed in clinical trials in endemic areas potentially offering a key treatment option for Lassa fever.",
author = "Robert Cross and Hastie, {Kathryn M.} and Chad Mire and Robinson, {James E.} and Thomas Geisbert and Branco, {Luis M.} and {Ollmann Saphire}, E. and Garry, {Robert F.}",
year = "2019",
month = "8",
day = "1",
doi = "10.1016/j.coviro.2019.07.003",
language = "English (US)",
volume = "37",
pages = "97--104",
journal = "Current Opinion in Virology",
issn = "1879-6257",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Antibody therapy for Lassa fever

AU - Cross, Robert

AU - Hastie, Kathryn M.

AU - Mire, Chad

AU - Robinson, James E.

AU - Geisbert, Thomas

AU - Branco, Luis M.

AU - Ollmann Saphire, E.

AU - Garry, Robert F.

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Serum from convalescent Lassa fever patients was previously shown to be ineffective as a source of protective antibodies in some early studies. Subsequently, monoclonal antibodies (MAbs) to the Lassa virus (LASV) glycoprotein produced by memory B cells of West African patients who survived Lassa fever were identified. Development of MAbs as potential Lassa immunotherapeutics was facilitated by structural studies and mutational analyses that identified protective epitopes on the prefusion form of the LASV glycoprotein. Human mAbs were screened for reactivity to different neutralizing epitopes, potency, and broad reactivity against multiple lineages of LASV. MAbs were downselected in a guinea pig model of Lassa fever. A cocktail of three human MAbs designated Arevirumab-3 rescued 100% of Cynomolgus macaques at advanced stages of disease more than a week post-infection. Antibody therapeutics may be further developed in clinical trials in endemic areas potentially offering a key treatment option for Lassa fever.

AB - Serum from convalescent Lassa fever patients was previously shown to be ineffective as a source of protective antibodies in some early studies. Subsequently, monoclonal antibodies (MAbs) to the Lassa virus (LASV) glycoprotein produced by memory B cells of West African patients who survived Lassa fever were identified. Development of MAbs as potential Lassa immunotherapeutics was facilitated by structural studies and mutational analyses that identified protective epitopes on the prefusion form of the LASV glycoprotein. Human mAbs were screened for reactivity to different neutralizing epitopes, potency, and broad reactivity against multiple lineages of LASV. MAbs were downselected in a guinea pig model of Lassa fever. A cocktail of three human MAbs designated Arevirumab-3 rescued 100% of Cynomolgus macaques at advanced stages of disease more than a week post-infection. Antibody therapeutics may be further developed in clinical trials in endemic areas potentially offering a key treatment option for Lassa fever.

UR - http://www.scopus.com/inward/record.url?scp=85070240249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070240249&partnerID=8YFLogxK

U2 - 10.1016/j.coviro.2019.07.003

DO - 10.1016/j.coviro.2019.07.003

M3 - Review article

AN - SCOPUS:85070240249

VL - 37

SP - 97

EP - 104

JO - Current Opinion in Virology

JF - Current Opinion in Virology

SN - 1879-6257

ER -